Curative cell and gene therapies and healthcare system disruption
SHARES
Introduction
Significant scientific advances have created a rich clinical research pipeline, with innovative and potentially curative cell and gene therapies already available (eg, Kymriah
® for acute lymphoblastic leukaemia, Luxturna
® for inherited retinal disease and Zolgensma
® for spinal muscular atrophy). Over the next 10 years, more of these therapies are expected to enter the market for other disease areas and larger patient populations. Potentially curative cell and gene therapies represent a key shift in patient care and will have considerable impact across the patient journey, affecting the healthcare system as we know it and the key stakeholders involved. Their launch is also met with significant debate over the uncertainty of outcomes’ durability and safety over the longer term; and the impact of treatment prices on affordability as more treatments enter the market. We draw from the chara
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Form 8-K Orchard Therapeutics For: May 13
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany
Update on OTL-200 U.S. BLA Filing Strategy for MLD on Track for Mid-2021 Following Type B RMAT Meeting with FDA
Recent Publications, Including ADA-SCID Dataset in NEJM and Multiple Oral Presentations at ASGCT, Highlight Broad and Innovative Potential of HSC Gene Therapy
Cash and Investments of Approximately $300M Provide Runway into First Half 2023 Following $150M Financing in February 2021
BOSTON and LONDON, May 13, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial results for the quarter ended March 31, 2021, as well as recent business updates and upcoming milestones.
Health policy panel discusses alternative national health care systems
Pete Rosos/Creative Commons
On May 7, Berkeley health policy scholars discussed lessons and ideas for possible health reform using studies of other health systems around the world. (Photo by Pete Rosos under CC BY-SA 2.0.)
The conference was a collaboration between the Gilbert Center and the College of Letters and Science.
Titled “Lessons for U.S. Health Reform: Ideas from Health Care Around the World,” the webinar was introduced by Jonathon Kolstad, associate professor of the Haas School of Business, as he elaborated on the role that social factors play in the health care system. Kolstad also said in the conference that the United States’ cost of health care was growing as a share of the gross domestic product, or GDP.